Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources
WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013. This growth will be fueled by a large increase in non-small-cell lung cancer diagnosed incident cases, improvement in access to medical care and significantly increased prescribing of targeted therapies.
"Urbanization and an aging population will result in a 47 percent increase in the number of diagnosed incident cases of non-small-cell lung cancer in China during 2008 to 2018. The most significant increase will occur in urban China, where we expect the number of diagnosed incident cases to increase 72 percent, in contrast to just eight percent in rural regions by the end of the 2018," stated Jing Wu, M.S., MBA.
The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in China also finds that increased penetration of current targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's Tarceva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's Erbitux (cetuximab) -- are the main driving forces in the Chinese non-small-cell lung cancer market from 2008 to 2013.
"In 2008, sales of non-small-cell lung cancer drugs in China totaled $307 million -- a 13 percent increase from our 2006 report," added Ms. Wu. "In 2008, the increased prescription of Iressa, Tarceva and Endostar was the major factor contributing to this market growth."
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved